Domain Therapeutics Doses First Patients in Phase I/II Trial of DT-7012 Targeting CCR8 in Solid Tumors
DT-7012 is a proprietary, differentiated Treg-depleting anti-CCR8 monoclonal antibody Differentiated binding capacities and competitive properties position it as a promising…
